A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for ...

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone ...

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Updated ACS guidance suggests use in those who decline other options ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

A systematic review was conducted to examine the potential impact of new molecular‐based screening tests on CRC incidence and mortality.

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...

The American Cancer Society released new recommendations to “close the screening gap” and catch more cancer cases at a ...

Revolution Medicines’ success in pancreatic cancer has ignited interest in a new type of medicine that’s sending dealmaking into overdrive.